Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVBPRO)

Drug Name
CP-673451 Drug Info
Synonyms CP-673,451
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10158940
ChEBI ID
CHEBI:131173
CAS Number
CAS 343787-29-1
TTD Drug ID
DMVBPRO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Platelet-derived growth factor receptor alpha (PDGFRA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [3]
Ripretinib DM958QB Gastrointestinal stromal tumour 2B5B Approved [4]
Olaratumab DMNYOIX Soft tissue sarcoma 2B57 Approved [5]
Avapritinib DMK2GZX Gastrointestinal stromal tumour 2B5B Approved [6]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [7]
CP-868596 DMZIM37 Gastrointestinal cancer 2C11 Phase 3 [8]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
MP470 DMELUAK Solid tumour/cancer 2A00-2F9Z Phase 2 [11]
MEDI-575 DMI9WVM Glioblastoma multiforme 2A00.0 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Tyrosine-protein kinase Kit (KIT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [13]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [14]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [15]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [16]
Ponatinib DMYGJQO Acute lymphoblastic leukaemia 2A85 Approved [16]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [17]
Pexidartinib DMS2J0Z Tenosynovial giant cell tumour 2F7B Approved [18]
Ripretinib DM958QB Gastrointestinal stromal tumour 2B5B Approved [4]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Platelet-derived growth factor receptor beta (PDGFRB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [14]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [3]
Becaplermin DM1R5X4 Diabetic complication 5A2Y Approved [19]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [7]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [20]
SNN-0031 DM2X3BR Brain injury NA07.Z Phase 1/2 [21]
TAK-593 DMNFZOT Solid tumour/cancer 2A00-2F9Z Phase 1 [22]
Pyridine derivative 18 DMBZMYT N. A. N. A. Patented [23]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Heme oxygenase 1 (HMOX1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [24]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [25]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [26]
Verapamil DMA7PEW Angina pectoris BA40 Approved [27]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [28]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [29]
Selenium DM25CGV N. A. N. A. Approved [30]
TECFIDERA DM2OVDT Multiple sclerosis 8A40 Approved [31]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [32]
Methotrexate DM2TEOL Anterior urethra cancer Approved [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By NAD(P)H dehydrogenase 1 (NQO1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [34]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [35]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [36]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [37]
TECFIDERA DM2OVDT Multiple sclerosis 8A40 Approved [38]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [39]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [40]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [41]
Quercetin DM3NC4M Obesity 5B81 Approved [42]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Nuclear factor erythroid 2-related factor 2 (NFE2L2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [44]
Verapamil DMA7PEW Angina pectoris BA40 Approved [27]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [45]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [37]
Selenium DM25CGV N. A. N. A. Approved [46]
TECFIDERA DM2OVDT Multiple sclerosis 8A40 Approved [47]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [40]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [41]
Quercetin DM3NC4M Obesity 5B81 Approved [48]
Furazolidone DM3P6V7 Diarrhea ME05.1 Approved [49]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Platelet-derived growth factor receptor alpha (PDGFRA) TT8FYO9 PGFRA_HUMAN Inhibitor [1]
Platelet-derived growth factor receptor beta (PDGFRB) TTI7421 PGFRB_HUMAN Inhibitor [1]
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Gene/Protein Processing [2]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Gene/Protein Processing [2]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Gene/Protein Processing [2]

References

1 Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res. 2005 Feb 1;65(3):957-66.
2 Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism. Toxicol Lett. 2018 Oct 1;295:88-98.
3 Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
5 A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
7 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
8 The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.
9 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
10 National Cancer Institute Drug Dictionary (drug id 452042).
11 Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
12 Clinical pipeline report, company report or official report of MedImmune (2011).
13 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
14 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
15 New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
16 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
17 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
18 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
19 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
20 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
21 Company report (Neuronova)
22 Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
23 RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
24 Dexamethasone and the inflammatory response in explants of human omental adipose tissue. Mol Cell Endocrinol. 2010 Feb 5;315(1-2):292-8.
25 Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
26 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
27 Protective role of HO-1 for alcohol-dependent liver damage. Dig Dis. 2010;28(6):792-8. doi: 10.1159/000324287. Epub 2011 Apr 27.
28 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
29 Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
30 High selenium status in individuals exposed to arsenic through coal-burning in Shaanxi (PR of China) modulates antioxidant enzymes, heme oxygenase-1 and DNA damage. Clin Chim Acta. 2010 Sep 6;411(17-18):1312-8.
31 Dimethyl Fumarate Inhibits the Nuclear Factor B Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein. J Biol Chem. 2016 Feb 12;291(7):3639-47. doi: 10.1074/jbc.M115.679704. Epub 2015 Dec 18.
32 Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncol Rep. 2008 Aug;20(2):379-84.
33 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
34 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
35 Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes. Arch Toxicol. 2018 Jan;92(1):371-381.
36 Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
37 Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
38 Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. Anticancer Drugs. 2005 Feb;16(2):167-74.
39 Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer. 2000 Dec 15;88(6):873-80. doi: 10.1002/1097-0215(20001215)88:6<873::aid-ijc6>3.0.co;2-b.
40 Simvastatin protects dopaminergic neurons against MPP+-induced oxidative stress and regulates the endogenous anti-oxidant system through ERK. Cell Physiol Biochem. 2018;51(4):1957-1968.
41 P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
42 Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin. Toxicol Lett. 2001 Feb 3;119(1):49-57.
43 Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
44 Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. J Cell Biochem. 2017 Apr;118(4):819-828. doi: 10.1002/jcb.25757. Epub 2016 Nov 28.
45 Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
46 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
47 Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease. J Neurosci. 2016 Jun 8;36(23):6332-51. doi: 10.1523/JNEUROSCI.0426-16.2016.
48 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
49 P21(Waf1/Cip1) plays a critical role in furazolidone-induced apoptosis in HepG2 cells through influencing the caspase-3 activation and ROS generation. Food Chem Toxicol. 2016 Feb;88:1-12. doi: 10.1016/j.fct.2015.12.004. Epub 2015 Dec 11.